Literature DB >> 17108072

Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease.

Silke Besier1, Christina Smaczny, Christian von Mallinckrodt, Andreas Krahl, Hanns Ackermann, Volker Brade, Thomas A Wichelhaus.   

Abstract

Small-colony variants (SCVs) of Staphylococcus aureus can be isolated from the chronically infected airways of patients suffering from cystic fibrosis (CF). These slow-growing morphological variants have been associated with persistent and antibiotic-resistant infections, such as osteomyelitis and device-related infections, but no information is available to date regarding the clinical significance of this special phenotype in CF lung disease. We therefore investigated the prevalence of S. aureus SCVs in CF lung disease in a 12-month prospective study and correlated the microbiological culture results with the patients' clinical data. A total of 252 patients were screened for the presence of SCVs. The prevalence rate was determined to be 17% (95% confidence interval, 10 to 25%) among S. aureus carriers. S. aureus isolates with the SCV phenotype showed significantly higher antibiotic resistance rates than those with the normal phenotype. Patients positive for SCVs were significantly older (P = 0.0099), more commonly cocolonized with Pseudomonas aeruginosa (P = 0.0454), and showed signs of more advanced disease, such as lower forced expiratory volume in 1 s (P = 0.0148) than patients harboring S. aureus with a solely normal phenotype. The logistic regression model determined lower weight (P = 0.016), advanced age (P = 0.000), and prior use of trimethoprim-sulfamethoxazole (P = 0.002) as independent risk factors for S. aureus SCV positivity. The clinical status of CF patients is known to be affected by multiple parameters. Nonetheless, the independent risk factors determined here point to the impact of S. aureus SCVs on chronic and persistent infections in advanced CF lung disease.

Entities:  

Mesh:

Year:  2006        PMID: 17108072      PMCID: PMC1828983          DOI: 10.1128/JCM.01510-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Recurrent infections by a stable dwarf-colony variant of Staphylococcus aureus.

Authors:  J G GOUDIE; R B GOUDIE
Journal:  J Clin Pathol       Date:  1955-11       Impact factor: 3.411

Review 2.  Cystic fibrosis.

Authors:  B J Rosenstein; P L Zeitlin
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

3.  Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S Häussler; B Tümmler; H Weissbrodt; M Rohde; I Steinmetz
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

4.  A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly.

Authors:  C von Eiff; C Heilmann; R A Proctor; C Woltz; G Peters; F Götz
Journal:  J Bacteriol       Date:  1997-08       Impact factor: 3.490

5.  Persistent wound infection after herniotomy associated with small-colony variants of Staphylococcus aureus.

Authors:  M Abele-Horn; B Schupfner; P Emmerling; H Waldner; H Göring
Journal:  Infection       Date:  2000 Jan-Feb       Impact factor: 3.553

6.  Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis.

Authors:  B Kahl; M Herrmann; A S Everding; H G Koch; K Becker; E Harms; R A Proctor; G Peters
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

7.  Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.

Authors:  C H Goss; N Mayer-Hamblett; M L Aitken; G D Rubenfeld; B W Ramsey
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

8.  Rapid detection of epidemic strains of methicillin-resistant Staphylococcus aureus.

Authors:  T A Wichelhaus; S Kern; V Schäfer; V Brade
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus.

Authors:  R A Proctor; P van Langevelde; M Kristjansson; J N Maslow; R D Arbeit
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

10.  Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis.

Authors:  P H Gilligan; P A Gage; D F Welch; M J Muszynski; K R Wait
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

View more
  59 in total

1.  Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.

Authors:  Anne Sandberg; Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens; Diarmaid Hughes; Christof von Eiff; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Tedizolid is a promising antimicrobial option for the treatment of Staphylococcus aureus infections in cystic fibrosis patients.

Authors:  Melanie Roch; Maria Celeste Varela; Agustina Taglialegna; Adriana E Rosato
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

3.  Comparative physiological study of the wild type and the small colony variant of Pseudomonas aeruginosa 20265 under controlled growth conditions.

Authors:  W Sabra; A M Haddad; A-P Zeng
Journal:  World J Microbiol Biotechnol       Date:  2013-10-16       Impact factor: 3.312

4.  Tomatidine inhibits replication of Staphylococcus aureus small-colony variants in cystic fibrosis airway epithelial cells.

Authors:  Gabriel Mitchell; Mariza Gattuso; Gilles Grondin; Éric Marsault; Kamal Bouarab; François Malouin
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

Review 5.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 6.  Hypermutation and stress adaptation in bacteria.

Authors:  R Jayaraman
Journal:  J Genet       Date:  2011-08       Impact factor: 1.166

Review 7.  Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.

Authors:  Edward Geisinger; Ralph R Isberg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

8.  Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.

Authors:  Laura M Filkins; Jyoti A Graber; Daniel G Olson; Emily L Dolben; Lee R Lynd; Sabin Bhuju; George A O'Toole
Journal:  J Bacteriol       Date:  2015-04-27       Impact factor: 3.490

9.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Anne Theunis; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

10.  Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide.

Authors:  Gabriel Mitchell; David Lalonde Séguin; Ann-Elise Asselin; Eric Déziel; André M Cantin; Eric H Frost; Sophie Michaud; François Malouin
Journal:  BMC Microbiol       Date:  2010-01-30       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.